论文部分内容阅读
病毒性肝炎肝功能衰竭患者行肝脏移植术后，病毒性肝炎的复发是影响其生存率的主要因素。但是，近年来随着对病毒性肝炎发病机制认识的加深和新型抗病毒药物的不断问世，其复发率得到良好控制。由于供者短缺，有些移植中心甚至采用肝炎病毒阳性的供者，同时使用抗病毒药物，实行抗病毒治疗和免疫治疗，短期随访效果良好。乙型肝炎所致的终末期肝硬化患者行肝移植后，应用乙型肝炎免疫球蛋白和抗病毒药物拉米夫定进行治疗；对于丙型肝炎则主要应用干扰素与利巴洛韦。近来研究多采用联合用药。今后，核苷酸类似物、反义核苷酸和免疫疫苗的应用为病毒性肝炎的防治带来新的希望。
Viral hepatitis, liver failure patients underwent liver transplantation, viral hepatitis recurrence is the main factor affecting the survival rate. However, with the deepening of the understanding of the pathogenesis of viral hepatitis and the advent of new antiviral drugs in recent years, the recurrence rate is well controlled. Due to a shortage of donors, some transplant centers even use hepatitis A virus-positive donors, and at the same time use antiviral drugs, antiviral therapy and immunotherapy, with good short-term follow-up. Hepatitis B caused by end-stage liver cirrhosis patients undergoing liver transplantation, the application of hepatitis B immunoglobulin and anti-viral lamivudine treatment; for hepatitis C is the main application of interferon and ribavir. Recently more research using combination therapy. In the future, the application of nucleotide analogues, antisense nucleotides and immune vaccines will bring new hope for the prevention and treatment of viral hepatitis.